NYMOX PHARMACEUTICAL CORP
NYMXF$6M
Micro CapNASDAQIn Vitro & In Vivo Diagnostic Substances🇺🇸North AmericaQUEBEC CANADA
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
NYMXF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
NX-1207
Benign Prostatic Hyperplasia (BPH)
NX-1207 2.5 mg
Prostate Cancer
2.5 mg NX-1207
Benign Prostatic Hyperplasia (BPH)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NX-1207 | Phase 3 | Benign Prostatic Hyperplasia (BPH) | - | - |
NX-1207 2.5 mg | Phase 2 | Prostate Cancer | - | - |
2.5 mg NX-1207 | Phase 2 | Benign Prostatic Hyperplasia (BPH) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply